WallStreetZenWallStreetZen

NASDAQ: RAPP
Rapport Therapeutics Inc Stock Ownership - Who owns Rapport Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Rapport Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
David BredtChief Scientific Officer2025-06-168,500$11.00
$93.53kSell
David BredtChief Scientific Officer2025-05-158,500$9.56
$81.26kSell
David BredtChief Scientific Officer2025-04-158,500$9.57
$81.31kSell
David BredtChief Scientific Officer2025-03-148,500$10.85
$92.21kSell
Troy A. IgnelziChief Financial Officer2025-03-13100$9.98
$998.00Buy
Troy A. IgnelziChief Financial Officer2025-03-129,900$10.10
$99.99kBuy
Wendy B. YoungDirector2025-03-126,000$10.21
$61.25kBuy

1 of 1

RAPP insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RAPP insiders and whales buy or sell their stock.

RAPP Shareholders

What type of owners hold Rapport Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Third Rock Ventures V LP22.21%8,104,451$124.65MInsider
Trv GP V LLC19.55%7,135,233$109.74MInstitution
Fmr LLC15.03%5,486,468$84.38MInstitution
Arch Venture Partners XII LLC10.22%3,728,738$57.35MInsider
Arch Venture Management LLC10.22%3,728,738$57.35MInstitution
Cormorant Asset Management LP8.06%2,940,921$45.23MInstitution
Capital International Investors7.13%2,602,529$40.03MInstitution
Johnson Johnson6.84%2,498,051$38.42MInstitution
Sofinnova Investments Inc5.47%1,995,594$30.69MInstitution
James Healy5.47%1,995,594$30.69MInsider

1 of 3

RAPP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RAPP70.15%29.85%Net SellingNet Selling
ORKA17.17%82.83%Net Buying
BCAX69.70%30.30%Net BuyingNet Buying
PGEN22.67%77.33%Net BuyingNet Selling
ATAI10.93%36.61%Net Buying
View Top Biotech Stocks

Rapport Therapeutics Stock Ownership FAQ

Who owns Rapport Therapeutics?

Rapport Therapeutics (NASDAQ: RAPP) is owned by 104.40% institutional shareholders, 44.43% Rapport Therapeutics insiders, and 0.00% retail investors. Third Rock Ventures V LP is the largest individual Rapport Therapeutics shareholder, owning 8.10M shares representing 22.21% of the company. Third Rock Ventures V LP's Rapport Therapeutics shares are currently valued at $118.32M.

If you're new to stock investing, here's how to buy Rapport Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.